rosoxacin

그림문자(GHS)

• 그림문자(GHS)

  

• 신호 어

  Warning

• 유해·위험 문구

  H302：삼키면 유해함

  H315：피부에 자극을 일으킴

  H319：눈에 심한 자극을 일으킴

  H335：호흡 자극성을 일으킬 수 있음

• 예방조치문구

  P261：분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.

  P280：보호장갑/보호의/보안경/안면보호구를 착용하시오.

  P301+P312：삼켜서 불편함을 느끼면 의료기관(의사)의 진찰을 받으시오.

  P302+P352：피부에 묻으면 다량의 물로 씻으시오.

  P305+P351+P338：눈에 묻으면 몇 분간 물로 조심해서 씻으시오. 가능하면 콘택트렌즈를 제거하시오. 계속 씻으시오.

rosoxacin 화학적 특성, 용도, 생산

• 용도

  Antibacterial.

• 정의

  ChEBI: A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by an ethyl group at position 1 and by a pyridin-4-yl group at position 7. An antibacterial drug, active against Neisseria gonorrhoeae, it has be n used for treating urinary tract infections and certain sexually transmitted diseases.

• Pharmacokinetics

  A single oral dose of 300 mg produces a mean peak plasma concentration of 4–5 mg/L at about 2–4 h, with an apparent elimination half-life of about 6 h. Elimination in the urine is partly as the N-oxide metabolite and the glucuronide of this metabolite.
  Side effects are those common to quinolones, notably gastrointestinal tract and CNS disturbances. About 50% of patients treated with single oral doses of 100–400 mg developed dizziness, drowsiness, altered visual perception and other CNS effects.
  It is effective as single-dose treatment of patients with urethral and anorectal gonorrhea, but coexistent C. trachomatis infection is not eliminated from most patients and postgonococcal urethritis develops in up to 30%.

rosoxacin 공급 업체

Global(30)Suppliers

rosoxacin 관련 검색